Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cellphire Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are being handled by 2 distinct examiners, introducing different examiner perspectives into the company's prosecution efforts. However, both actions are located within 1 distinct art unit, which indicates a specific technical focus for the company's current pending applications.
MATALKAH, FATIMAH KHALAF is identified as the busiest examiner for the portfolio, with 1 pending office action currently assigned. Since the total number of pending actions is 2, the workload is split between MATALKAH, FATIMAH KHALAF and one other examiner, with each handling 1 pending action. This arrangement allows the company to compare the examination styles of 2 different officials while benefiting from the technical consistency of a single art unit.
The presence of 2 pending office actions in 1 distinct art unit suggests that Cellphire Inc. is pursuing a narrow but active intellectual property strategy in the Biotechnology & Pharmaceuticals sector. Practitioners should leverage the consistency of the art unit to refine their arguments, while remaining attentive to the individual preferences of the examiners. This structure simplifies the technical coordination of the company's current docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | KASAYAN, KATRIEL BARCELLANO | 54d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | MATALKAH, FATIMAH KHALAF | — | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112Other | Non-Final OA | 54d | Pending | Jun 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial